The lipid lowering drugs market was valued at USD 20,605.0 Mn by 2019. The rising prevalence of hyperlipidemia in the young adult population worldwide primarily drives the lipid lowering drugs market growth. Promising drug pipeline and effective implementation of treatment guidelines for lowering blood cholesterol levels further accentuate the market growth.

Hyperlipidemia is the most predominant risk factor associate with the high mortality rate I patients suffering from coronary artery disease. As per the latest statistics provided by the World Health Organization (WHO), it is anticipated that high blood cholesterol levels are responsible annually for 2.6 million deaths and 29.7 million disability-adjusted life years (DALYs), throughout the globe. The medications need to be taken under strict medical supervision to prevent the occurrence of unwanted drug-related adverse events.

The major segments related to the lipid lowering drugs market are: 

By Drug Class (2017–2027; US$ Mn)

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

PCSK9 Inhibitors

Combination

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global lipid lowering drugs market
• The overall segmentation of the lipid lowering drugs market, by drug class, distribution channel and geography is minutely studied. Statins and hospital pharmacy are dominating the drug class and distribution channel segments respectively
• Rising prevalence of obesity and hyperlipidemia together drive the market growth
• The constant rise in the number of patients suffering from coronary artery disease due to high blood cholesterol levels further accentuate the market growth

Report gist?

• The study of the global lipid lowering drugs market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of drug class and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of lipid lowering drugs due to the rising prevalence of hyperlipidemia worldwide
• The report will benefit formulation scientist engaged in the development of combination drug therapy for lowering blood cholesterol levels
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to lipid lowering drugs market
• Financial institutions, venture capitalists, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies. 

Segment Analysis

Statins are representing the largest market share in the drug class segment for lipid lowering drugs market. It is the most frequently prescribed medication for lowering the high blood cholesterol levels via the inhibition of HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase which is a rate-limiting enzyme in the cholesterol biosynthesis pathway. In the last 2 decades, it has been vital in lowering the mortality rate associated with coronary artery disease worldwide. PCSK9 inhibitors are expected to highlight excellent market growth during the forecast period owing to its pronounced therapeutic efficacy in statin-intolerant and statin resistant patients. It is vital in lowering the number of LDLR expression in the hepatocytes and enhances its metabolism by promoting its subsequent degradation.

Hospital pharmacy is reigning the distribution channel segment for lipid lowering drugs market. Precise dispensing of lipid lowering drugs by hospital pharmacists is mandatory as the majority of them are associated with serious side effects such as skin rashes, dizziness, sleep problems, etc. Retail pharmacy is expected to grow at a comfortable pace owing of the provision of government-subsidized lipid lowering drugs at lower affordable prices in the retail stores of the developing region.

North America is presently leading the geography segment for lipid lowering drugs market. The growing incidence of high blood cholesterol levels among the young population primarily drives the market growth in the region. The presence of well-established healthcare infrastructure and affordable reimbursement scenarios together accentuate the market growth in the region. Furthermore, the domicile of major players such as Pfizer, Inc., Amgen, Inc., Merck Co., Inc., AbbVie, Inc., etc further propels the market growth in the region. Europe is the second-largest regional segment due to the effective implementation of the treatment guidelines postulated by the European Medical Agency (EMA), for the treatment of hyperlipidemia prevalent in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the lipid lowering drugs market. An unhealthy lifestyle, craving for junk food, stress, etc. are responsible for the market growth in the region.